Subtopic Deep Dive

Topoisomerase Genetic Variants
Research Guide

What is Topoisomerase Genetic Variants?

Topoisomerase genetic variants refer to polymorphisms in TOP1 and TOP2A genes that modulate enzyme activity, chemotherapy drug sensitivity, and patient outcomes in cancer treatment.

These variants, such as promoter polymorphisms in TOP2A, predict responses to drugs like etoposide and cisplatin in lung and gastric cancers (Grenda et al., 2019; Cao et al., 2017). Studies link TOP2A and ERCC1 SNPs to efficacy and toxicity in small cell lung cancer patients (Nicoś et al., 2020). Over 10 papers since 2016 explore these associations, with citation leaders examining multidrug resistance and pharmacogenomics.

Curated Papers

Key Challenges

Why It Matters

TOP2A promoter polymorphisms predict chemotherapy outcomes in non-small cell lung cancer, enabling personalized dosing to reduce toxicity (Grenda et al., 2019, 29 citations). In gastric cancer, TOP2A expression alongside UGT1A1 variants guides treatment selection to improve survival (Cao et al., 2017, 23 citations). Pharmacogenetic screening for TOP2A/ERCC1 SNPs in small cell lung cancer optimizes cisplatin-etoposide regimens, minimizing adverse effects (Nicoś et al., 2020, 10 citations). These insights support precision oncology by tailoring anthracycline doses to genetic profiles, reducing cardiotoxicity (Scott et al., 2018).

Key Research Challenges

Predicting Clinical Outcomes

TOP2A polymorphisms show variable predictive power across cancer types, complicating generalized models (Grenda et al., 2019). Studies in lung cancer link ERCC1/TOP2A SNPs to etoposide response but require larger cohorts for validation (Nicoś et al., 2020).

Multi-Factorial Resistance

Multidrug resistance in leukemia involves TOP2A alongside genomic changes, hindering isolation of variant effects (Kadioglu et al., 2016, 44 citations). Transcriptomic profiling reveals complex interactions needing integrative analysis.

Translating to Therapy

Despite TOP2A variant associations, routine pharmacogenomic testing lags due to inconsistent replication (Scott et al., 2018). Glioblastoma trials highlight personalization challenges with topoisomerase II poisons (Mehta et al., 2018).

Essential Papers

HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II

Michal Štros, Eva Polanská, Soňa Štruncová et al. · 2009 · Nucleic Acids Research · 49 citations

Topoisomerase IIalpha (topo IIalpha) is a nuclear enzyme involved in several critical processes, including chromosome replication, segregation and recombination. Previously we have shown that chrom...

Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistance

Onat Kadioglu, Jingming Cao, Nadezda Kosyakova et al. · 2016 · Scientific Reports · 44 citations

Abstract We systematically characterised multifactorial multidrug resistance (MDR) in CEM/ADR5000 cells, a doxorubicin-resistant sub-line derived from drug-sensitive, parental CCRF-CEM cells develo...

Topoisomerase II contributes to DNA secondary structure-mediated double-stranded breaks

Karol Szlachta, Arkadi Manukyan, Heather M. Raimer et al. · 2020 · Nucleic Acids Research · 37 citations

Abstract DNA double-stranded breaks (DSBs) trigger human genome instability, therefore identifying what factors contribute to DSB induction is critical for our understanding of human disease etiolo...

Promoter polymorphisms of <i>TOP2A</i> and <i>ERCC1</i> genes as predictive factors for chemotherapy in non‐small cell lung cancer patients

Anna Grenda, Justyna Błach, Michał Szczyrek et al. · 2019 · Cancer Medicine · 29 citations

Abstract Background Topoisomerase 2‐alpha ( TOP2A ) is an enzyme that controls topologic changes in DNA during transcription and replication. ERCC1 is an enzyme that takes part in DNA repair proces...

Physiological Roles of DNA Double-Strand Breaks

Farhaan Khan, Syed O. Ali · 2017 · Journal of Nucleic Acids · 27 citations

Genomic integrity is constantly threatened by sources of DNA damage, internal and external alike. Among the most cytotoxic lesions is the DNA double-strand break (DSB) which arises from the cleavag...

Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer

Yongkuan Cao, Zhang Guo-hu, Peihong Wang et al. · 2017 · BMC Gastroenterology · 23 citations

Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy

Amol Mehta, Chidiebere U. Awah, Adam M. Sonabend · 2018 · Frontiers in Neurology · 23 citations

Despite advances in surgery, radiotherapy, and chemotherapy, glioblastoma (GBM) remains a malignancy with poor prognosis. The molecular profile of GBM is diverse across patients, and individual res...

Reading Guide

Foundational Papers

Start with Štros et al. (2009, 49 citations) for HMGB1-TOP2A regulation mechanisms underlying variant effects.

Recent Advances

Study Grenda et al. (2019) for TOP2A polymorphisms in lung cancer prediction and Nicoś et al. (2020) for SCLC chemotherapy associations.

Core Methods

SNP genotyping, RNA sequencing for expression (Kadioglu et al., 2016), promoter polymorphism assays, and pharmacogenetic modeling with survival analysis.

How PapersFlow Helps You Research Topoisomerase Genetic Variants

Discover & Search

Research Agent uses searchPapers and exaSearch to find TOP2A polymorphism studies, then citationGraph on Grenda et al. (2019) reveals 29 citing papers on lung cancer pharmacogenomics. findSimilarPapers expands to gastric cancer variants from Cao et al. (2017).

Analyze & Verify

Analysis Agent applies readPaperContent to extract SNP data from Nicoś et al. (2020), then runPythonAnalysis with pandas to compute odds ratios for TOP2A/ERCC1 efficacy. verifyResponse (CoVe) and GRADE grading confirm claims against Kadioglu et al. (2016) multidrug resistance profiles, flagging contradictions.

Synthesize & Write

Synthesis Agent detects gaps in TOP2A variant replication across cancers, while Writing Agent uses latexEditText and latexSyncCitations to draft pharmacogenomic models citing Štros et al. (2009). exportMermaid generates pathway diagrams of HMGB1-TOP2A interactions; latexCompile produces publication-ready reviews.

Use Cases

"Run statistical analysis on TOP2A SNP frequencies in lung cancer cohorts from recent papers."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of Grenda et al. 2019 and Nicoś et al. 2020 SNP data) → matplotlib survival plots output.

"Write a LaTeX review on TOP2A pharmacogenetics for precision oncology."

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Štros 2009, Grenda 2019) → latexCompile → PDF with cited pharmacogenomic table.

"Find code for modeling topoisomerase variant drug sensitivity."

Research Agent → paperExtractUrls (Kadioglu 2016) → paperFindGithubRepo → githubRepoInspect → Python scripts for RNA-seq MDR analysis output.

Automated Workflows

Deep Research workflow scans 50+ topoisomerase papers via searchPapers, structures pharmacogenomic reports with GRADE-verified variant impacts from Grenda et al. (2019). DeepScan's 7-step chain analyzes Nicoś et al. (2020) SNPs with runPythonAnalysis checkpoints for toxicity prediction. Theorizer generates hypotheses on TOP2A-HMGB1 interactions from Štros et al. (2009) for novel inhibitors.

Try Doxa for Topoisomerase Genetic Variants Research

Frequently Asked Questions

What defines topoisomerase genetic variants?

Polymorphisms in TOP1 and TOP2A genes that alter enzyme activity and chemotherapy responses, such as TOP2A promoter SNPs predicting lung cancer outcomes (Grenda et al., 2019).

What methods study these variants?

Genotyping for TOP2A/ERCC1 SNPs, transcriptomic profiling in resistant cells, and association studies with survival/toxicity (Kadioglu et al., 2016; Nicoś et al., 2020).

What are key papers?

Štros et al. (2009, 49 citations) on HMGB1 regulating TOP2A; Grenda et al. (2019, 29 citations) on predictive polymorphisms in lung cancer.

What open problems exist?

Validating TOP2A variants across diverse populations and integrating with multi-omics for robust pharmacogenomic models (Scott et al., 2018; Mehta et al., 2018).